Eric J. Sherman, MD, on the Efficacy of Cabozantinib in Refractory Differentiated Thyroid Cancer

Video

Eric J. Sherman, MD, examines the phase 3 COSMIC-311 trial with cabozantinib in radioiodine-refractory differentiated thyroid cancer.

At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® sat down with Eric J. Sherman, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, to discuss the efficacy of the tyrosine kinase inhibitor (TKI) cabozantinib (Cabometyx) in radioiodine-refractory differentiated thyroid cancer, as seen in the phase 3 COSMIC-311 trial (NCT03690388). Data from the trial revealed that cabozantinib yielded a notable benefit in progression-free survival (PFS) and has the potential to change clinical practice.

Transcript:

Another [study] that may change practice [is] a randomized phase 3 study of cabozantinib vs placebo that Marcia S. Brose, MD, PhD, of the Perelman School of Medicine at the University of Pennsylvania, presented as part of the head neck oral session. That was also a positive study. It was only in patients who had prior VEGF TKIs. It was either in the second- or third-line [setting]. Patients [had to have] either [prior] sorafenib [Nexavar], lenvatinib [Lenvima] or both...and shown progression. [This trial] also showed a gigantic progression-free survival [benefit]; it was so big that the study was stopped early. There are a lot of questions still. We do not know what the true median PFS was because most patients were censored even before 9 months. The study reported early and we do not know what the mature data show.

Reference

Brose MS, Robinson , Sherman SI, et al. Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: results from the phase 3 COSMIC-311 trial. J Clin Oncol. 2021;39(suppl 15):6001. doi:10.1200/JCO.2021.39.15_suppl.6001

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Related Content